RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
Zacks·7d ago
More News
JPMorgan Chase & Co. Has Lowered Expectations for Revvity (NYSE:RVTY) Stock Price
JPMorgan Chase & Co. decreased their target price on shares of Revvity from $96.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday...
MarketBeat·15d ago
TD Cowen Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock
TD Cowen raised their target price on Revvity from $115.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday...
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.
Zacks·16d ago
Revvity (NYSE:RVTY) Posts Earnings Results, Beats Expectations By $0.04 EPS
Revvity (NYSE:RVTY - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.04. The...
MarketBeat·16d ago
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·16d ago
Revvity Q1 Earnings Call Highlights
Revvity (NYSE:RVTY) reported first-quarter 2026 results that came in ahead of its expectations and outlined a planned divestiture of its immunodiagnostics business in China, a move management said will sharpen the company's focus and improve growth and profitability metrics going forward.
First-qua...
MarketBeat·16d ago
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
Revvity (RVTY) delivered earnings and revenue surprises of +4.10% and +0.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Revvity (NYSE:RVTY) updated its FY 2026 earnings guidance. The company provided EPS guidance of 5.200-5.300 for the period, compared to the consensus estimate of 5.400. The company also issued revenue guidance of $2.8 billionillion-$2.8 billionillion, compared to the consensus estimate of $3.0...
MarketBeat·16d ago
Revvity Q1 26 Earnings Conference Call At 7:30 AM ET
(RTTNews) - Revvity, Inc. (RVTY) will host a conference call at 7.30 AM ET on May 5, 2026, to discuss Q1 26 earnings results...